CESVONO Trademark

Trademark Overview


On Thursday, October 22, 2020, a trademark application was filed for CESVONO with the United States Patent and Trademark Office. The USPTO has given the CESVONO trademark a serial number of 90271697. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 13, 2022. This trademark is owned by Bristol-Myers Squibb Company. The CESVONO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pha...
cesvono

General Information


Serial Number90271697
Word MarkCESVONO
Filing DateThursday, October 22, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 13, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 14, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for use in disease testing
Translation of Words in MarkThe word(s) "CESVONO" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 10, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Monday, June 13, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 13, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, November 9, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021PUBLISHED FOR OPPOSITION
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, August 6, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 6, 2021EXAMINER'S AMENDMENT ENTERED
Friday, August 6, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, August 6, 2021EXAMINERS AMENDMENT E-MAILED
Friday, August 6, 2021EXAMINERS AMENDMENT -WRITTEN
Wednesday, July 28, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 27, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 27, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 29, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 29, 2021NON-FINAL ACTION E-MAILED
Friday, January 29, 2021NON-FINAL ACTION WRITTEN
Wednesday, January 27, 2021ASSIGNED TO EXAMINER
Thursday, December 10, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, October 26, 2020NEW APPLICATION ENTERED IN TRAM